These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20093182)

  • 1. Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor.
    Nadarassan DK; Assi KH; Chrystyn H
    Eur J Pharm Sci; 2010 Mar; 39(5):348-54. PubMed ID: 20093182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: the influence of flow and volume.
    Yakubu SI; Assi KH; Chrystyn H
    Int J Pharm; 2013 Oct; 455(1-2):213-8. PubMed ID: 23892154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler.
    Tarsin W; Assi KH; Chrystyn H
    J Aerosol Med; 2004; 17(1):25-32. PubMed ID: 15120010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a Turbuhaler at low inhalation flow.
    Abdelrahim ME; Assi KH; Chrystyn H
    Pharm Dev Technol; 2013; 18(4):944-9. PubMed ID: 21981637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler.
    Abadelah M; Hazim F; Chrystyn H; Bagherisadeghi G; Rahmoune H; Larhrib H
    Eur J Pharm Sci; 2017 Jun; 104():180-187. PubMed ID: 28351669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol.
    Weda M; Zanen P; de Boer AH; Barends DM; Frijlink HW
    Int J Pharm; 2004 Dec; 287(1-2):79-87. PubMed ID: 15541915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors.
    Taki M; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2010 Mar; 388(1-2):40-51. PubMed ID: 20026261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
    Feddah MR; Brown KF; Gipps EM; Davies NM
    J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler.
    Abadelah M; Chrystyn H; Larhrib H
    Eur J Pharm Sci; 2019 Jun; 134():138-144. PubMed ID: 31005623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates.
    Yoshida H; Kuwana A; Shibata H; Izutsu KI; Goda Y
    AAPS PharmSciTech; 2017 Apr; 18(3):646-653. PubMed ID: 27173989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerodynamic characteristics of nebulized terbutaline sulphate using the Andersen Cascade Impactor compared to the Next Generation Impactor.
    Abdelrahim ME
    Pharm Dev Technol; 2011 Apr; 16(2):137-45. PubMed ID: 20100034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
    Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
    AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
    Tarsin WY; Pearson SB; Assi KH; Chrystyn H
    Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen eight-stage cascade impactor (ACI).
    Mohammed H; Roberts DL; Copley M; Hammond M; Nichols SC; Mitchell JP
    AAPS PharmSciTech; 2012 Sep; 13(3):875-82. PubMed ID: 22678745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of dry powder inhaler (DPI) resistance and aerosol dispersion timing on emitted aerosol aerodynamic particle sizing by multistage cascade impactor when sampled volume is reduced from compendial value of 4 L.
    Mohammed H; Arp J; Chambers F; Copley M; Glaab V; Hammond M; Solomon D; Bradford K; Russell T; Sizer Y; Nichols SC; Roberts DL; Shelton C; Greguletz R; Mitchell JP
    AAPS PharmSciTech; 2014 Oct; 15(5):1126-37. PubMed ID: 24871551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines.
    Wong W; Crapper J; Chan HK; Traini D; Young PM
    J Pharm Biomed Anal; 2010 Mar; 51(4):853-7. PubMed ID: 19932579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet.
    Mitchell J; Copley M; Sizer Y; Russell T; Solomon D
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):188-97. PubMed ID: 22857270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery.
    Onoue S; Yamamoto K; Kawabata Y; Hirose M; Mizumoto T; Yamada S
    Int J Pharm; 2009 Dec; 382(1-2):144-50. PubMed ID: 19703531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.